Array Biopharma, Inc. (ARRY) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.93 +1.81%
EPS Growth %: -70.0%
Financial Fact:
Net loss: -28.61M
Today's EPS Names:
OCCI, IPX, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
Net loss: -28.61M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and memory not a classic bubble, but future returns uncertain - strategist
- Citi raises Okta price target to $205, keeps Neutral rating
- Paychex (PAYX) PT Lowered to $115 at UBS on Pace of Revenue Growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
